4.7 C
New York
Wednesday, December 6, 2023

Akero Therapeutics Inc (NASDAQ: AKRO) Could Achieve Gains In The Near Future

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Akero Therapeutics Inc (AKRO) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.28, or -1.79%, to $15.34. The Akero Therapeutics Inc has recorded 20,121 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update.

Stocks Info

Akero Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $15.62 and fluctuated between $15.66 as its day high and $14.41 as its day low. The current market capitalization of Akero Therapeutics Inc is $870.19M. A total of 1.37 million shares were traded on the day, compared to an average of 1.82M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, AKRO has seen 6 BUY and 17 SELL insider trades, representing the acquisition of 76,235 and the disposition of 65,259 shares. Over the last 12 months, there were 36 BUYs and 81 SELLs from insiders. Insiders purchased 703,159 shares during that period but sold 2,214,151.

In the most recent transaction, Cheng Andrew sold 25,000 shares of AKRO for 47.91 per share on Oct 02. After the transaction, the President and CEO now owns 460,998 company shares. In a previous transaction on Oct 02, Young Jonathan sold 490 shares at 51.10 per share. AKRO shares that Chief Operating Officer owns now total 183,177.

Among the insiders who sold shares, Yale Catriona disposed of 5,000 shares on Sep 21 at a per-share price of $48.07. This resulted in the Chief Development Officer holding 46,010 shares of AKRO after the transaction. In another insider transaction, Graham G. Walmsley bought 400,000 shares at $26.00 per share on Sep 19. Company shares held by the Director now total 400,000.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for AKRO in the last 3 months, the mean price target is $42.88 with high estimates of $60.00 and low estimates of $33.00. In terms of 52-week highs and lows, AKRO has a high of $58.38 and a low of $11.25.

As of this writing, AKRO has an earnings estimate of -$0.86 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.67 per share and a lower estimate of -$1.09. The company reported an EPS of -$0.6 in the last quarter, which was 4.80% higher than expectations of -$0.63.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. AKRO’s latest balance sheet shows that the firm has $188.26M in Cash & Short Term Investments as of fiscal 2021. There were $1.52M in debt and $25.13M in liabilities at the time. Its Book Value Per Share was $10.47, while its Total Shareholder’s Equity was $169.11M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKRO is Buy with a score of 5.00.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles